07:23pm Friday 22 September 2017

Novel software application can stratify early-stage non-small cell lung cancer patients into risk categories based on analysis of computed tomography images.

The majority of NSCLC patients are diagnosed with advanced-stage disease which is concomitant with an exceptionally poor prognosis, 5-year survival rate of 4%. In contrast, tumors detected at an early stage have 5-year survival rates of 54%. The National Lung Cancer Screening Trial (NLST) demonstrated a 20% reduction in lung-cancer specific mortality by screening with HRCT, but many detected nodules are  non-cancerous and slow-growing, which can lead to costly and risky overdiagnosis and overtreatment. Thus, better risk classification based on the nodules characteristics is desirable.

HRCT images from 264 clinical stage I pulmonary nodules of the lung adenocarcinoma spectrum were analyzed with the CANARY system and the software used an unsupervised clustering algorithm to classify the patients into categories of similar nodule characteristics.

The results published in the November issue of the Journal of Thoracic Oncology, the official journal for the International Association for the Study of Lung Cancer (IASLC), show that the adenocarcinomas naturally segregated into 3 groups based on HRCT characteristics. The three identified groups corresponded to good, intermediate, and poor postoperative outcomes with 5-year disease-free survival rates of 100%, 73% and 51%, respectively.

“Our preliminary assessment suggests CANARY represents a robust risk stratification tool that can be utilized with a wide variety of HRCT techniques and equipment for retrospective or prospective evaluation of lung nodules in a real-world setting”, conclude the authors. Dr. Raghunath, lead author of the study, suggests “HRCT-based CANARY classification could ultimately guide the individualized treatment of HRCT-detected lesions with nodules noninvasively categorized as “good” managed with less aggressive surgical approaches, noninvasive or minimally invasive therapy or watchful waiting, whereas nodules that have characteristics corresponding to the “poor” group would be managed with current standard of care, such as lobectomy, and perhaps additional adjuvant therapy.”

Co-authors Drs. Fabien Maldonado,Tobias Peikert, and Brian Bartholmai are members of IASLC.

-30-

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 4,000 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org

Murry W. Wynes, PhD
IASLC Special Projects Manager
Murry.Wynes@IASLC.org
(720) 325-2945


Share on:
or:

Health news